[ FDA ENFORCEMENT INTELLIGENCE ]
Learn from the record. Every FDA recall is a quality signal.
Live drug, device & food recall data from the FDA (openFDA enforcement) — food spanning dietary supplements, cosmetics & animal food — mapped to the GxP quality domains SPEQ assesses, so you can see where control breaks down across every regulated industry.
1,000
Total recalls
217
Class I (most serious)
167
Drug
515
Device
318
Food / supplement / cosmetic
Last 12 months · latest report 2026-07-22 · source: openFDA enforcement
RECALLS BY CLASSIFICATION · MONTHLY
RECALL REASONS BY QUALITY DOMAIN
Domain mapping is a SPEQ interpretation of the FDA recall reason, not an official FDA classification.
839 matching recalls
| Date | Class | Firm | Reason | Quality domain |
|---|---|---|---|---|
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0573-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0559-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0575-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0570-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class III | Eugia US LLCD-0552-2026 | Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan | Documentation & Change Control |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0576-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Ascend Laboratories, LLCD-0556-2026 | Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications | Validation & Qualification |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0571-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0574-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0569-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | SUN PHARMACEUTICAL INDUSTRIES INCD-0598-2026 | Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona | Documentation & Change Control |
| 2026-06-10 | Class II | Lannett Company Inc.D-0584-2026 | Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint. | Validation & Qualification |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0572-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0579-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0560-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Spectra Medical Devices, LlcD-0554-2026 | Lack of Assurance of Sterility | Environmental Monitoring |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0565-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0566-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Asclemed USA Inc.D-0555-2026 | CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit. | Validation & Qualification |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0558-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0562-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | SUN PHARMACEUTICAL INDUSTRIES INCD-0599-2026 | Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona | Documentation & Change Control |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0561-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-10 | Class II | Guardian Drug Co. Inc.D-0568-2026 | Presence of foreign substance: small metallic particles in chewable tablets. | — |
| 2026-06-03 | Class III | AVEVA Drug Delivery Systems, Inc.D-0550-2026 | Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of individual units. | Validation & Qualification |
Data: U.S. FDA openFDA enforcement API. Quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Recall details are as reported by the FDA.